No offense but what you said makes absolutely no logical sense unless I’m reading what you said wrong. Or the process is more broken than I thought.

Why would they do a interim look at 75 percent only to have them increase the trial size? Wouldn’t it make more sense just to say continue to 390 and finish it?

Go look at Otto Yangs paper and graph. I’m shocked the trial wasn’t stopped for efficiency this last time. I think that’s what we are aiming for, at the 75 percent mark, just need a little more data for approval.

You seem to always be negative.